#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Progressive	_
1-2	12-30	Symptom-Associated	_
1-3	31-41	Prefrontal	_
1-4	42-48	Volume	_
1-5	49-53	Loss	_
1-6	54-60	Occurs	_
1-7	61-63	in	_
1-8	64-77	First-Episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-9	78-91	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-10	92-95	but	_
1-11	96-99	not	_
1-12	100-102	in	_
1-13	103-112	Affective	http://maven.renci.org/NeuroBridge/neurobridge#MixedBipolarAffectiveDisorder
1-14	113-122	Psychosis	_
1-15	123-131	Although	_
1-16	132-139	smaller	_
1-17	140-144	gray	_
1-18	145-151	matter	_
1-19	152-159	volumes	_
1-20	160-161	(	_
1-21	162-165	GMV	_
1-22	166-167	)	_
1-23	168-170	in	_
1-24	171-174	the	_
1-25	175-185	prefrontal	_
1-26	186-192	cortex	_
1-27	193-194	(	_
1-28	195-198	PFC	_
1-29	199-200	)	_
1-30	201-203	in	_
1-31	204-217	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-32	218-221	and	_
1-33	222-229	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-34	230-238	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-35	239-243	have	_
1-36	244-248	been	_
1-37	249-257	reported	_
1-38	258-275	cross-sectionally	_
1-39	276-277	,	_
1-40	278-283	there	_
1-41	284-287	are	_
1-42	288-289	,	_
1-43	290-292	to	_
1-44	293-296	our	_
1-45	297-306	knowledge	_
1-46	307-308	,	_
1-47	309-311	no	_
1-48	312-319	reports	_
1-49	320-322	of	_
1-50	323-335	longitudinal	_
1-51	336-347	comparisons	_
1-52	348-353	using	_
1-53	354-362	manually	_
1-54	363-368	drawn	_
1-55	369-370	,	_
1-56	371-384	gyrally-based	_
1-57	385-388	ROI	_
1-58	389-390	,	_
1-59	391-394	and	_
1-60	395-400	their	_
1-61	401-413	associations	_
1-62	414-418	with	_
1-63	419-427	symptoms	_
1-64	428-429	.	_

2-1	430-433	The	_
2-2	434-440	object	_
2-3	441-443	of	_
2-4	444-448	this	_
2-5	449-454	study	_
2-6	455-458	was	_
2-7	459-461	to	_
2-8	462-471	determine	_
2-9	472-479	whether	_
2-10	480-493	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-11	494-507	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-12	508-509	(	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-13	510-514	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-14	515-516	)	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
2-15	517-520	and	_
2-16	521-534	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-17	535-544	affective	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-18	545-554	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-19	555-556	(	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-20	557-562	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-21	563-564	)	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-22	565-573	patients	_
2-23	574-578	show	_
2-24	579-586	initial	_
2-25	587-590	and	_
2-26	591-602	progressive	_
2-27	603-606	PFC	_
2-28	607-610	GMV	_
2-29	611-620	reduction	_
2-30	621-623	in	_
2-31	624-633	bilateral	_
2-32	634-641	frontal	_
2-33	642-646	pole	_
2-34	647-648	,	_
2-35	649-657	superior	_
2-36	658-665	frontal	_
2-37	666-671	gyrus	_
2-38	672-673	(	_
2-39	674-677	SFG	_
2-40	678-679	)	_
2-41	680-681	,	_
2-42	682-688	middle	_
2-43	689-696	frontal	_
2-44	697-702	gyrus	_
2-45	703-704	(	_
2-46	705-708	MFG	_
2-47	709-710	)	_
2-48	711-712	,	_
2-49	713-716	and	_
2-50	717-725	inferior	_
2-51	726-733	frontal	_
2-52	734-739	gyrus	_
2-53	740-741	(	_
2-54	742-745	IFG	_
2-55	746-747	)	_
2-56	748-751	and	_
2-57	752-759	examine	_
2-58	760-765	their	_
2-59	766-773	symptom	_
2-60	774-786	associations	_
2-61	787-788	.	_

3-1	789-799	Twenty-one	_
3-2	800-804	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
3-3	805-806	,	_
3-4	807-809	24	_
3-5	810-815	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
3-6	816-819	and	_
3-7	820-822	23	_
3-8	823-830	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-9	831-838	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-10	839-847	subjects	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-11	848-849	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-12	850-852	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-13	853-854	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-14	855-864	underwent	_
3-15	865-869	1.5T	_
3-16	870-873	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
3-17	874-878	with	_
3-18	879-888	follow-up	_
3-19	889-896	imaging	_
3-20	897-899	on	_
3-21	900-903	the	_
3-22	904-908	same	_
3-23	909-916	scanner	_
3-24	917-918	~	_
3-25	919-922	1.5	_
3-26	923-928	years	_
3-27	929-934	later	_
3-28	935-936	.	_

4-1	937-943	Groups	_
4-2	944-948	were	_
4-3	949-959	strikingly	_
4-4	960-969	different	_
4-5	970-972	in	_
4-6	973-984	progressive	_
4-7	985-988	GMV	_
4-8	989-993	loss	_
4-9	994-995	.	_

5-1	996-1000	FESZ	_
5-2	1001-1007	showed	_
5-3	1008-1019	significant	_
5-4	1020-1031	progressive	_
5-5	1032-1035	GMV	_
5-6	1036-1040	loss	_
5-7	1041-1043	in	_
5-8	1044-1047	the	_
5-9	1048-1052	left	_
5-10	1053-1056	SFG	_
5-11	1057-1058	,	_
5-12	1059-1068	bilateral	_
5-13	1069-1072	MFG	_
5-14	1073-1074	,	_
5-15	1075-1078	and	_
5-16	1079-1088	bilateral	_
5-17	1089-1092	IFG	_
5-18	1093-1094	.	_

6-1	1095-1097	In	_
6-2	1098-1106	addition	_
6-3	1107-1108	,	_
6-4	1109-1113	left	_
6-5	1114-1117	MFG	_
6-6	1118-1124	and/or	_
6-7	1125-1128	IFG	_
6-8	1129-1132	GMV	_
6-9	1133-1137	loss	_
6-10	1138-1141	was	_
6-11	1142-1152	associated	_
6-12	1153-1157	with	_
6-13	1158-1167	worsening	_
6-14	1168-1170	of	_
6-15	1171-1193	withdrawal-retardation	_
6-16	1194-1197	and	_
6-17	1198-1203	total	_
6-18	1204-1208	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
6-19	1209-1217	symptoms	_
6-20	1218-1224	scores	_
6-21	1225-1226	.	_

7-1	1227-1229	In	_
7-2	1230-1238	contrast	_
7-3	1239-1240	,	_
7-4	1241-1246	FEAFF	_
7-5	1247-1253	showed	_
7-6	1254-1256	no	_
7-7	1257-1268	significant	_
7-8	1269-1279	difference	_
7-9	1280-1282	in	_
7-10	1283-1286	GMV	_
7-11	1287-1295	compared	_
7-12	1296-1300	with	_
7-13	1301-1303	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-14	1304-1305	,	_
7-15	1306-1312	either	_
7-16	1313-1330	cross-sectionally	_
7-17	1331-1333	or	_
7-18	1334-1348	longitudinally	_
7-19	1349-1350	.	_

8-1	1351-1353	Of	_
8-2	1354-1358	note	_
8-3	1359-1360	,	_
8-4	1361-1371	FreeSurfer	_
8-5	1372-1375	run	_
8-6	1376-1378	on	_
8-7	1379-1382	the	_
8-8	1383-1387	same	_
8-9	1388-1394	images	_
8-10	1395-1401	showed	_
8-11	1402-1404	no	_
8-12	1405-1416	significant	_
8-13	1417-1424	changes	_
8-14	1425-1439	longitudinally	_
8-15	1440-1441	.	_

9-1	1442-1449	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-2	1450-1462	Participants	_
9-3	1463-1466	The	_
9-4	1467-1479	participants	_
9-5	1480-1484	were	_
9-6	1485-1495	twenty-one	_
9-7	1496-1504	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-8	1505-1509	with	_
9-9	1510-1514	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
9-10	1515-1518	and	_
9-11	1519-1521	24	_
9-12	1522-1526	with	_
9-13	1527-1532	FEAFF	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
9-14	1533-1534	(	_
9-15	1535-1537	22	_
9-16	1538-1540	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-17	1541-1543	in	_
9-18	1544-1545	a	_
9-19	1546-1551	manic	_
9-20	1552-1557	phase	_
9-21	1558-1561	and	_
9-22	1562-1563	2	_
9-23	1564-1568	with	_
9-24	1569-1570	a	_
9-25	1571-1579	unipolar	_
9-26	1580-1590	depression	_
9-27	1591-1600	diagnosis	_
9-28	1601-1603	at	_
9-29	1604-1607	the	_
9-30	1608-1612	time	_
9-31	1613-1615	of	_
9-32	1616-1619	the	_
9-33	1620-1625	scans	_
9-34	1626-1629	who	_
9-35	1630-1635	later	_
9-36	1636-1642	showed	_
9-37	1643-1644	a	_
9-38	1645-1650	manic	_
9-39	1651-1656	phase	_
9-40	1657-1658	)	_
9-41	1659-1662	and	_
9-42	1663-1665	23	_
9-43	1666-1669	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-44	1670-1671	(	_
9-45	1672-1677	Table	_
9-46	1678-1679	1	_
9-47	1680-1681	)	_
9-48	1682-1683	.	_

10-1	1684-1691	Briefly	_
10-2	1692-1693	,	_
10-3	1694-1697	the	_
10-4	1698-1706	criteria	_
10-5	1707-1709	of	_
10-6	1710-1713	the	_
10-7	1714-1722	subjects	_
10-8	1723-1726	are	_
10-9	1727-1729	as	_
10-10	1730-1737	follows	_
10-11	1738-1739	.	_

11-1	1740-1748	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-2	1749-1752	and	_
11-3	1753-1756	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-4	1757-1760	met	_
11-5	1761-1769	criteria	_
11-6	1770-1773	for	_
11-7	1774-1777	age	_
11-8	1778-1779	(	_
11-9	1780-1785	18–45	_
11-10	1786-1791	years	_
11-11	1792-1793	)	_
11-12	1794-1795	,	_
11-13	1796-1798	IQ	_
11-14	1799-1800	(	_
11-15	1801-1802	>	_
11-16	1803-1805	75	_
11-17	1806-1807	)	_
11-18	1808-1809	,	_
11-19	1810-1826	right-handedness	_
11-20	1827-1828	(	_
11-21	1829-1839	handedness	_
11-22	1840-1843	was	_
11-23	1844-1852	assessed	_
11-24	1853-1858	using	_
11-25	1859-1862	the	_
11-26	1863-1872	Edinburgh	_
11-27	1873-1882	inventory	_
11-28	1883-1884	)	_
11-29	1885-1886	,	_
11-30	1887-1890	and	_
11-31	1891-1892	a	_
11-32	1893-1901	negative	_
11-33	1902-1909	history	_
11-34	1910-1913	for	_
11-35	1914-1922	seizures	_
11-36	1923-1924	,	_
11-37	1925-1929	head	_
11-38	1930-1936	trauma	_
11-39	1937-1941	with	_
11-40	1942-1946	loss	_
11-41	1947-1949	of	_
11-42	1950-1963	consciousness	_
11-43	1964-1965	,	_
11-44	1966-1976	neurologic	_
11-45	1977-1985	disorder	_
11-46	1986-1987	,	_
11-47	1988-1991	and	_
11-48	1992-1994	no	_
11-49	1995-2002	history	_
11-50	2003-2005	of	_
11-51	2006-2010	drug	_
11-52	2011-2021	dependence	_
11-53	2022-2024	in	_
11-54	2025-2028	the	_
11-55	2029-2033	past	_
11-56	2034-2035	5	_
11-57	2036-2041	years	_
11-58	2042-2043	.	_

12-1	2044-2051	Patient	_
12-2	2052-2061	diagnosis	_
12-3	2062-2065	was	_
12-4	2066-2071	based	_
12-5	2072-2074	on	_
12-6	2075-2078	the	_
12-7	2079-2089	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-8	2090-2098	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-9	2099-2108	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-10	2109-2112	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-11	2113-2116	DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-12	2117-2118	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-13	2119-2123	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-14	2124-2125	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-15	2126-2134	–Patient	_
12-16	2135-2142	Version	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-17	2143-2146	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-18	2147-2156	DSM-III-R	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-19	2157-2159	or	_
12-20	2160-2166	DSM-IV	_
12-21	2167-2175	criteria	_
12-22	2176-2177	.	_

13-1	2178-2181	The	_
13-2	2182-2185	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
13-3	2186-2189	had	_
13-4	2190-2192	no	_
13-5	2193-2197	Axis	_
13-6	2198-2199	I	_
13-7	2200-2202	or	_
13-8	2203-2207	Axis	_
13-9	2208-2210	II	_
13-10	2211-2219	disorder	_
13-11	2220-2229	according	_
13-12	2230-2232	to	_
13-13	2233-2236	the	_
13-14	2237-2253	SCID-Non-Patient	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-15	2254-2261	Version	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-16	2262-2265	and	_
13-17	2266-2270	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-18	2271-2273	II	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-19	2274-2285	Personality	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-20	2286-2295	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-21	2296-2297	,	_
13-22	2298-2301	and	_
13-23	2302-2304	no	_
13-24	2305-2309	Axis	_
13-25	2310-2311	I	_
13-26	2312-2320	disorder	_
13-27	2321-2323	in	_
13-28	2324-2329	their	_
13-29	2330-2342	first-degree	_
13-30	2343-2352	relatives	_
13-31	2353-2356	per	_
13-32	2357-2368	self-report	_
13-33	2369-2370	.	_

14-1	2371-2374	All	_
14-2	2375-2378	the	_
14-3	2379-2387	subjects	_
14-4	2388-2392	were	_
14-5	2393-2407	longitudinally	_
14-6	2408-2418	re-scanned	_
14-7	2419-2432	approximately	_
14-8	2433-2436	1.5	_
14-9	2437-2442	years	_
14-10	2443-2448	later	_
14-11	2449-2450	(	_
14-12	2451-2456	Table	_
14-13	2457-2458	2	_
14-14	2459-2460	)	_
14-15	2461-2462	.	_

15-1	2463-2472	Excluding	_
15-2	2473-2476	the	_
15-3	2477-2478	2	_
15-4	2479-2487	subjects	_
15-5	2488-2497	initially	_
15-6	2498-2507	diagnosed	_
15-7	2508-2510	as	_
15-8	2511-2519	unipolar	_
15-9	2520-2523	but	_
15-10	2524-2529	later	_
15-11	2530-2535	found	_
15-12	2536-2538	to	_
15-13	2539-2541	be	_
15-14	2542-2547	manic	_
15-15	2548-2551	did	_
15-16	2552-2555	not	_
15-17	2556-2562	change	_
15-18	2563-2566	the	_
15-19	2567-2578	statistical	_
15-20	2579-2586	results	_
15-21	2587-2589	in	_
15-22	2590-2593	the	_
15-23	2594-2609	cross-sectional	_
15-24	2610-2612	or	_
15-25	2613-2616	the	_
15-26	2617-2629	longitudinal	_
15-27	2630-2636	sample	_
15-28	2637-2638	.	_

16-1	2639-2642	The	_
16-2	2643-2658	cross-sectional	_
16-3	2659-2662	and	_
16-4	2663-2675	longitudinal	_
16-5	2676-2682	groups	_
16-6	2683-2687	were	_
16-7	2688-2695	matched	_
16-8	2696-2699	for	_
16-9	2700-2703	age	_
16-10	2704-2705	,	_
16-11	2706-2709	sex	_
16-12	2710-2711	,	_
16-13	2712-2722	handedness	_
16-14	2723-2724	,	_
16-15	2725-2728	and	_
16-16	2729-2737	parental	_
16-17	2738-2751	socioeconomic	_
16-18	2752-2758	status	_
16-19	2759-2760	(	_
16-20	2761-2764	SES	_
16-21	2765-2766	)	_
16-22	2767-2768	.	_

17-1	2769-2779	Medication	_
17-2	2780-2787	history	_
17-3	2788-2789	,	_
17-4	2790-2792	if	_
17-5	2793-2800	present	_
17-6	2801-2802	,	_
17-7	2803-2806	was	_
17-8	2807-2815	assessed	_
17-9	2816-2818	by	_
17-10	2819-2826	patient	_
17-11	2827-2833	report	_
17-12	2834-2837	and	_
17-13	2838-2845	through	_
17-14	2846-2853	medical	_
17-15	2854-2859	chart	_
17-16	2860-2866	review	_
17-17	2867-2868	.	_

18-1	2869-2875	Dosage	_
18-2	2876-2877	(	_
18-3	2878-2883	Table	_
18-4	2884-2885	1	_
18-5	2886-2889	and	_
18-6	2890-2895	Table	_
18-7	2896-2897	3	_
18-8	2898-2899	)	_
18-9	2900-2902	of	_
18-10	2903-2917	antipsychotics	_
18-11	2918-2921	did	_
18-12	2922-2925	not	_
18-13	2926-2935	correlate	_
18-14	2936-2940	with	_
18-15	2941-2944	any	_
18-16	2945-2952	initial	_
18-17	2953-2959	volume	_
18-18	2960-2962	or	_
18-19	2963-2969	volume	_
18-20	2970-2976	change	_
18-21	2977-2978	.	_

19-1	2979-2987	Patients	_
19-2	2988-2992	were	_
19-3	2993-3002	recruited	_
19-4	3003-3005	at	_
19-5	3006-3012	McLean	_
19-6	3013-3021	Hospital	_
19-7	3022-3023	,	_
19-8	3024-3025	a	_
19-9	3026-3033	Harvard	_
19-10	3034-3041	Medical	_
19-11	3042-3048	School	_
19-12	3049-3058	affiliate	_
19-13	3059-3060	.	_

20-1	3061-3064	The	_
20-2	3065-3068	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-3	3069-3073	were	_
20-4	3074-3083	recruited	_
20-5	3084-3091	through	_
20-6	3092-3101	newspaper	_
20-7	3102-3116	advertisements	_
20-8	3117-3118	.	_

21-1	3119-3129	Consistent	_
21-2	3130-3134	with	_
21-3	3135-3138	the	_
21-4	3139-3149	literature	_
21-5	3150-3153	and	_
21-6	3154-3157	our	_
21-7	3158-3166	previous	_
21-8	3167-3174	studies	_
21-9	3175-3176	,	_
21-10	3177-3178	a	_
21-11	3179-3184	first	_
21-12	3185-3192	episode	_
21-13	3193-3196	was	_
21-14	3197-3210	operationally	_
21-15	3211-3218	defined	_
21-16	3219-3221	as	_
21-17	3222-3225	the	_
21-18	3226-3231	first	_
21-19	3232-3247	hospitalization	_
21-20	3248-3251	for	_
21-21	3252-3261	psychosis	_
21-22	3262-3263	.	_

22-1	3264-3272	Subjects	_
22-2	3273-3276	had	_
22-3	3277-3280	not	_
22-4	3281-3285	been	_
22-5	3286-3296	previously	_
22-6	3297-3309	hospitalized	_
22-7	3310-3313	for	_
22-8	3314-3317	any	_
22-9	3318-3329	psychiatric	_
22-10	3330-3336	reason	_
22-11	3337-3338	.	_

23-1	3339-3341	We	_
23-2	3342-3349	believe	_
23-3	3350-3354	this	_
23-4	3355-3364	criterion	_
23-5	3365-3367	is	_
23-6	3368-3378	consistent	_
23-7	3379-3382	and	_
23-8	3383-3389	robust	_
23-9	3390-3395	based	_
23-10	3396-3398	on	_
23-11	3399-3400	a	_
23-12	3401-3411	consequent	_
23-13	3412-3421	objective	_
23-14	3422-3428	record	_
23-15	3429-3431	of	_
23-16	3432-3440	symptoms	_
23-17	3441-3442	;	_
23-18	3443-3451	moreover	_
23-19	3452-3454	as	_
23-20	3455-3461	judged	_
23-21	3462-3464	by	_
23-22	3465-3468	the	_
23-23	3469-3474	onset	_
23-24	3475-3477	of	_
23-25	3478-3491	antipsychotic	_
23-26	3492-3502	medication	_
23-27	3503-3504	,	_
23-28	3505-3508	our	_
23-29	3509-3517	subjects	_
23-30	3518-3521	had	_
23-31	3522-3523	a	_
23-32	3524-3529	short	_
23-33	3530-3539	potential	_
23-34	3540-3549	psychosis	_
23-35	3550-3558	duration	_
23-36	3559-3564	prior	_
23-37	3565-3567	to	_
23-38	3568-3571	our	_
23-39	3572-3577	study	_
23-40	3578-3579	,	_
23-41	3580-3581	2	_
23-42	3582-3587	weeks	_
23-43	3588-3591	for	_
23-44	3592-3595	the	_
23-45	3596-3600	FESZ	_
23-46	3601-3604	and	_
23-47	3605-3606	1	_
23-48	3607-3611	week	_
23-49	3612-3615	for	_
23-50	3616-3621	FEAFF	_
23-51	3622-3623	.	_

24-1	3624-3628	This	_
24-2	3629-3634	study	_
24-3	3635-3638	was	_
24-4	3639-3647	approved	_
24-5	3648-3650	by	_
24-6	3651-3654	the	_
24-7	3655-3661	McLean	_
24-8	3662-3670	Hospital	_
24-9	3671-3672	,	_
24-10	3673-3681	Veterans	_
24-11	3682-3689	Affairs	_
24-12	3690-3696	Boston	_
24-13	3697-3707	Healthcare	_
24-14	3708-3714	System	_
24-15	3715-3716	,	_
24-16	3717-3720	and	_
24-17	3721-3728	Harvard	_
24-18	3729-3736	Medical	_
24-19	3737-3743	School	_
24-20	3744-3757	institutional	_
24-21	3758-3764	review	_
24-22	3765-3771	boards	_
24-23	3772-3773	.	_

25-1	3774-3781	Written	_
25-2	3782-3790	informed	_
25-3	3791-3798	consent	_
25-4	3799-3802	was	_
25-5	3803-3811	obtained	_
25-6	3812-3816	from	_
25-7	3817-3820	all	_
25-8	3821-3829	subjects	_
25-9	3830-3836	before	_
25-10	3837-3842	study	_
25-11	3843-3856	participation	_
25-12	3857-3858	.	_

26-1	3859-3867	Clinical	_
26-2	3868-3879	evaluations	_
26-3	3880-3882	at	_
26-4	3883-3888	times	_
26-5	3889-3890	1	_
26-6	3891-3894	and	_
26-7	3895-3896	2	_
26-8	3897-3905	included	_
26-9	3906-3909	the	_
26-10	3910-3914	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
26-11	3915-3918	and	_
26-12	3919-3922	the	_
26-13	3923-3931	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
26-14	3932-3937	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
26-15	3938-3950	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
26-16	3951-3964	Scale–Revised	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
26-17	3965-3966	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
26-18	3967-3973	WAIS-R	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
26-19	3974-3975	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
26-20	3976-3977	.	_

27-1	3978-3981	MRI	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
27-2	3982-3992	processing	http://maven.renci.org/NeuroBridge/neurobridge#AffectiveProcessingScale
27-3	3993-3996	The	_
27-4	3997-4000	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-5	4001-4009	protocol	_
27-6	4010-4014	used	_
27-7	4015-4016	2	_
27-8	4017-4022	pulse	_
27-9	4023-4032	sequences	_
27-10	4033-4035	on	_
27-11	4036-4037	a	_
27-12	4038-4042	1.5T	_
27-13	4043-4046	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-14	4047-4053	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
27-15	4054-4055	(	_
27-16	4056-4058	GE	_
27-17	4059-4066	Medical	_
27-18	4067-4074	Systems	_
27-19	4075-4076	,	_
27-20	4077-4086	Milwaukee	_
27-21	4087-4088	,	_
27-22	4089-4098	Wisconsin	_
27-23	4099-4100	)	_
27-24	4101-4102	,	_
27-25	4103-4105	as	_
27-26	4106-4115	described	_
27-27	4116-4118	by	_
27-28	4119-4122	and	_
27-29	4123-4126	our	_
27-30	4127-4140	supplementary	_
27-31	4141-4145	text	_
27-32	4146-4147	.	_

28-1	4148-4151	The	_
28-2	4152-4161	segmented	_
28-3	4162-4167	voxel	_
28-4	4168-4175	volumes	_
28-5	4176-4178	of	_
28-6	4179-4183	gray	_
28-7	4184-4187	and	_
28-8	4188-4193	white	_
28-9	4194-4200	matter	_
28-10	4201-4204	and	_
28-11	4205-4218	cerebrospinal	_
28-12	4219-4224	fluid	_
28-13	4225-4229	were	_
28-14	4230-4236	summed	_
28-15	4237-4239	to	_
28-16	4240-4245	yield	_
28-17	4246-4249	the	_
28-18	4250-4255	total	_
28-19	4256-4268	intracranial	_
28-20	4269-4277	contents	_
28-21	4278-4279	(	_
28-22	4280-4283	ICC	_
28-23	4284-4285	)	_
28-24	4286-4287	.	_

29-1	4288-4294	Region	_
29-2	4295-4297	of	_
29-3	4298-4306	interest	_
29-4	4307-4308	(	_
29-5	4309-4312	ROI	_
29-6	4313-4314	)	_
29-7	4315-4318	The	_
29-8	4319-4322	PFC	_
29-9	4323-4333	subregions	_
29-10	4334-4336	of	_
29-11	4337-4344	frontal	_
29-12	4345-4349	pole	_
29-13	4350-4351	(	_
29-14	4352-4354	FP	_
29-15	4355-4356	)	_
29-16	4357-4358	,	_
29-17	4359-4362	and	_
29-18	4363-4366	the	_
29-19	4367-4375	superior	_
29-20	4376-4377	,	_
29-21	4378-4384	middle	_
29-22	4385-4388	and	_
29-23	4389-4397	inferior	_
29-24	4398-4405	frontal	_
29-25	4406-4410	gyri	_
29-26	4411-4412	(	_
29-27	4413-4416	SFG	_
29-28	4417-4418	,	_
29-29	4419-4422	MFG	_
29-30	4423-4424	,	_
29-31	4425-4428	and	_
29-32	4429-4432	IFG	_
29-33	4433-4445	respectively	_
29-34	4446-4447	)	_
29-35	4448-4451	are	_
29-36	4452-4461	displayed	_
29-37	4462-4464	in	_
29-38	4465-4468	Fig	_
29-39	4469-4470	.	_

30-1	4471-4472	1	_
30-2	4473-4474	.	_

31-1	4475-4478	The	_
31-2	4479-4486	details	_
31-3	4487-4489	of	_
31-4	4490-4493	the	_
31-5	4494-4502	criteria	_
31-6	4503-4507	used	_
31-7	4508-4511	for	_
31-8	4512-4524	parcellation	_
31-9	4525-4528	are	_
31-10	4529-4533	also	_
31-11	4534-4543	described	_
31-12	4544-4546	in	_
31-13	4547-4550	our	_
31-14	4551-4564	supplementary	_
31-15	4565-4569	text	_
31-16	4570-4571	.	_

32-1	4572-4575	All	_
32-2	4576-4582	manual	_
32-3	4583-4586	ROI	_
32-4	4587-4600	parcellations	_
32-5	4601-4605	were	_
32-6	4606-4615	performed	_
32-7	4616-4618	by	_
32-8	4619-4632	investigators	_
32-9	4633-4638	blind	_
32-10	4639-4641	to	_
32-11	4642-4651	diagnoses	_
32-12	4652-4655	and	_
32-13	4656-4659	the	_
32-14	4660-4664	date	_
32-15	4665-4667	of	_
32-16	4668-4672	scan	_
32-17	4673-4674	.	_

33-1	4675-4677	To	_
33-2	4678-4684	assess	_
33-3	4685-4696	inter-rater	_
33-4	4697-4708	reliability	_
33-5	4709-4710	,	_
33-6	4711-4712	3	_
33-7	4713-4718	blind	_
33-8	4719-4725	raters	_
33-9	4726-4727	(	_
33-10	4728-4732	T.O.	_
33-11	4733-4734	,	_
33-12	4735-4739	T.A.	_
33-13	4740-4741	,	_
33-14	4742-4745	and	_
33-15	4746-4749	T.R	_
33-16	4750-4751	.	_
33-17	4752-4753	)	_

34-1	4754-4767	independently	_
34-2	4768-4778	delineated	_
34-3	4779-4782	the	_
34-4	4783-4787	ROIs	_
34-5	4788-4791	for	_
34-6	4792-4793	5	_
34-7	4794-4802	randomly	_
34-8	4803-4811	selected	_
34-9	4812-4817	cases	_
34-10	4818-4819	.	_

35-1	4820-4831	Intra-class	_
35-2	4832-4843	correlation	_
35-3	4844-4856	coefficients	_
35-4	4857-4860	for	_
35-5	4861-4864	the	_
35-6	4865-4871	volume	_
35-7	4872-4876	were	_
35-8	4877-4881	0.97	_
35-9	4882-4885	for	_
35-10	4886-4889	the	_
35-11	4890-4894	left	_
35-12	4895-4897	FP	_
35-13	4898-4899	,	_
35-14	4900-4904	0.98	_
35-15	4905-4908	for	_
35-16	4909-4912	the	_
35-17	4913-4918	right	_
35-18	4919-4921	FP	_
35-19	4922-4923	,	_
35-20	4924-4928	0.97	_
35-21	4929-4932	for	_
35-22	4933-4936	the	_
35-23	4937-4941	left	_
35-24	4942-4945	SFG	_
35-25	4946-4947	,	_
35-26	4948-4952	0.95	_
35-27	4953-4956	for	_
35-28	4957-4960	the	_
35-29	4961-4966	right	_
35-30	4967-4970	SFG	_
35-31	4971-4972	,	_
35-32	4973-4977	0.96	_
35-33	4978-4981	for	_
35-34	4982-4985	the	_
35-35	4986-4990	left	_
35-36	4991-4994	MFG	_
35-37	4995-4996	,	_
35-38	4997-5001	0.96	_
35-39	5002-5005	for	_
35-40	5006-5009	the	_
35-41	5010-5015	right	_
35-42	5016-5019	MFG	_
35-43	5020-5021	,	_
35-44	5022-5026	0.95	_
35-45	5027-5030	for	_
35-46	5031-5034	the	_
35-47	5035-5039	left	_
35-48	5040-5043	IFG	_
35-49	5044-5045	,	_
35-50	5046-5050	0.96	_
35-51	5051-5054	for	_
35-52	5055-5058	the	_
35-53	5059-5064	right	_
35-54	5065-5068	IFG	_
35-55	5069-5070	.	_

36-1	5071-5081	FreeSurfer	_
36-2	5082-5090	analysis	_
36-3	5091-5093	In	_
36-4	5094-5099	order	_
36-5	5100-5102	to	_
36-6	5103-5110	compare	_
36-7	5111-5114	the	_
36-8	5115-5122	ability	_
36-9	5123-5125	of	_
36-10	5126-5135	detecting	_
36-11	5136-5142	subtle	_
36-12	5143-5153	structural	_
36-13	5154-5161	changes	_
36-14	5162-5165	and	_
36-15	5166-5169	the	_
36-16	5170-5178	validity	_
36-17	5179-5181	of	_
36-18	5182-5188	manual	_
36-19	5189-5201	parcellation	_
36-20	5202-5206	with	_
36-21	5207-5210	the	_
36-22	5211-5214	use	_
36-23	5215-5217	of	_
36-24	5218-5227	automated	_
36-25	5228-5239	methodology	_
36-26	5240-5241	,	_
36-27	5242-5244	we	_
36-28	5245-5249	also	_
36-29	5250-5258	analyzed	_
36-30	5259-5262	the	_
36-31	5263-5266	ROI	_
36-32	5267-5274	volumes	_
36-33	5275-5280	using	_
36-34	5281-5291	FreeSurfer	_
36-35	5292-5299	version	_
36-36	5300-5303	5.3	_
36-37	5304-5305	(	_
36-38	5306-5311	https	_
36-39	5312-5313	:	_
36-40	5314-5342	//surfer.nmr.mgh.harvard.edu	_
36-41	5343-5344	)	_
36-42	5345-5346	.	_

37-1	5347-5351	Thus	_
37-2	5352-5353	,	_
37-3	5354-5357	the	_
37-4	5358-5361	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-5	5362-5367	scans	_
37-6	5368-5372	used	_
37-7	5373-5376	for	_
37-8	5377-5383	manual	_
37-9	5384-5396	parcellation	_
37-10	5397-5401	were	_
37-11	5402-5413	reprocessed	_
37-12	5414-5419	using	_
37-13	5420-5430	FreeSurfer	_
37-14	5431-5433	v.	_
37-15	5434-5437	5.3	_
37-16	5438-5439	.	_

38-1	5440-5443	One	_
38-2	5444-5446	of	_
38-3	5447-5450	the	_
38-4	5451-5458	coronal	_
38-5	5459-5464	slice	_
38-6	5465-5476	parcellated	_
38-7	5477-5479	by	_
38-8	5480-5490	FreeSurfer	_
38-9	5491-5493	v.	_
38-10	5494-5497	5.3	_
38-11	5498-5500	is	_
38-12	5501-5510	displayed	_
38-13	5511-5513	in	_
38-14	5514-5517	our	_
38-15	5518-5531	supplementary	_
38-16	5532-5535	Fig	_
38-17	5536-5537	.	_

39-1	5538-5540	S1	_
39-2	5541-5542	.	_

40-1	5543-5546	The	_
40-2	5547-5555	detailed	_
40-3	5556-5566	procedures	_
40-4	5567-5570	for	_
40-5	5571-5581	volumetric	_
40-6	5582-5594	measurements	_
40-7	5595-5597	of	_
40-8	5598-5600	FP	_
40-9	5601-5602	,	_
40-10	5603-5606	SFG	_
40-11	5607-5608	,	_
40-12	5609-5615	caudal	_
40-13	5616-5619	and	_
40-14	5620-5627	rostral	_
40-15	5628-5631	MFG	_
40-16	5632-5633	,	_
40-17	5634-5637	and	_
40-18	5638-5641	IFG	_
40-19	5642-5643	(	_
40-20	5644-5647	i.e	_
40-21	5648-5649	.	_

41-1	5650-5654	pars	_
41-2	5655-5666	opercularis	_
41-3	5667-5668	,	_
41-4	5669-5673	pars	_
41-5	5674-5683	orbitalis	_
41-6	5684-5685	,	_
41-7	5686-5689	and	_
41-8	5690-5694	pars	_
41-9	5695-5699	pars	_
41-10	5700-5709	orbitalis	_
41-11	5710-5711	)	_
41-12	5712-5716	have	_
41-13	5717-5721	been	_
41-14	5722-5731	described	_
41-15	5732-5734	in	_
41-16	5735-5742	several	_
41-17	5743-5755	publications	_
41-18	5756-5757	.	_

42-1	5758-5766	Relative	_
42-2	5767-5774	volumes	_
42-3	5775-5779	were	_
42-4	5780-5790	calculated	_
42-5	5791-5793	by	_
42-6	5794-5802	dividing	_
42-7	5803-5810	volumes	_
42-8	5811-5813	by	_
42-9	5814-5817	the	_
42-10	5818-5823	total	_
42-11	5824-5836	intracranial	_
42-12	5837-5843	volume	_
42-13	5844-5846	of	_
42-14	5847-5851	each	_
42-15	5852-5859	subject	_
42-16	5860-5862	as	_
42-17	5863-5871	provided	_
42-18	5872-5874	by	_
42-19	5875-5878	the	_
42-20	5879-5889	FreeSurfer	_
42-21	5890-5896	output	_
42-22	5897-5898	.	_

43-1	5899-5910	Statistical	_
43-2	5911-5919	Analysis	_
43-3	5920-5927	One-way	_
43-4	5928-5936	analysis	_
43-5	5937-5939	of	_
43-6	5940-5948	variance	_
43-7	5949-5950	(	_
43-8	5951-5956	ANOVA	_
43-9	5957-5958	)	_
43-10	5959-5962	was	_
43-11	5963-5972	performed	_
43-12	5973-5978	among	_
43-13	5979-5983	FESZ	_
43-14	5984-5985	,	_
43-15	5986-5991	FEAFF	_
43-16	5992-5993	,	_
43-17	5994-5997	and	_
43-18	5998-6000	HC	_
43-19	6001-6007	groups	_
43-20	6008-6011	for	_
43-21	6012-6015	age	_
43-22	6016-6017	,	_
43-23	6018-6028	inter-scan	_
43-24	6029-6037	interval	_
43-25	6038-6039	,	_
43-26	6040-6050	handedness	_
43-27	6051-6052	,	_
43-28	6053-6066	socioeconomic	_
43-29	6067-6073	status	_
43-30	6074-6075	(	_
43-31	6076-6079	SES	_
43-32	6080-6081	)	_
43-33	6082-6083	,	_
43-34	6084-6092	parental	_
43-35	6093-6096	SES	_
43-36	6097-6098	,	_
43-37	6099-6105	WAIS-R	_
43-38	6106-6117	Information	_
43-39	6118-6121	and	_
43-40	6122-6127	Digit	_
43-41	6128-6132	Span	_
43-42	6133-6139	scaled	_
43-43	6140-6146	scores	_
43-44	6147-6151	with	_
43-45	6152-6161	follow-up	_
43-46	6162-6166	post	_
43-47	6167-6170	hoc	_
43-48	6171-6176	Tukey	_
43-49	6177-6185	Honestly	_
43-50	6186-6197	Significant	_
43-51	6198-6208	Difference	_
43-52	6209-6210	(	_
43-53	6211-6214	HSD	_
43-54	6215-6216	)	_
43-55	6217-6222	tests	_
43-56	6223-6224	.	_

44-1	6225-6227	In	_
44-2	6228-6236	addition	_
44-3	6237-6238	,	_
44-4	6239-6246	t-tests	_
44-5	6247-6251	were	_
44-6	6252-6261	performed	_
44-7	6262-6269	between	_
44-8	6270-6274	FESZ	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
44-9	6275-6278	and	_
44-10	6279-6284	FEAFF	_
44-11	6285-6291	groups	_
44-12	6292-6295	for	_
44-13	6296-6304	duration	_
44-14	6305-6307	of	_
44-15	6308-6315	illness	_
44-16	6316-6317	,	_
44-17	6318-6328	medication	_
44-18	6329-6335	dosage	_
44-19	6336-6337	[	_
44-20	6338-6352	chlorpromazine	_
44-21	6353-6363	equivalent	_
44-22	6364-6377	antipsychotic	_
44-23	6378-6384	dosage	_
44-24	6385-6386	]	_
44-25	6387-6388	,	_
44-26	6389-6392	and	_
44-27	6393-6397	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
44-28	6398-6404	scores	_
44-29	6405-6406	.	_

45-1	6407-6412	Group	_
45-2	6413-6424	differences	_
45-3	6425-6427	in	_
45-4	6428-6431	PFC	_
45-5	6432-6435	GMV	_
45-6	6436-6438	at	_
45-7	6439-6444	times	_
45-8	6445-6446	1	_
45-9	6447-6450	and	_
45-10	6451-6452	2	_
45-11	6453-6457	were	_
45-12	6458-6463	first	_
45-13	6464-6472	assessed	_
45-14	6473-6478	using	_
45-15	6479-6487	repeated	_
45-16	6488-6496	measures	_
45-17	6497-6502	ANOVA	_
45-18	6503-6504	,	_
45-19	6505-6509	with	_
45-20	6510-6515	Group	_
45-21	6516-6518	as	_
45-22	6519-6522	the	_
45-23	6523-6539	between-subjects	_
45-24	6540-6546	factor	_
45-25	6547-6550	and	_
45-26	6551-6561	Hemisphere	_
45-27	6562-6563	(	_
45-28	6564-6568	left	_
45-29	6569-6572	and	_
45-30	6573-6578	right	_
45-31	6579-6580	)	_
45-32	6581-6584	and	_
45-33	6585-6591	Region	_
45-34	6592-6593	(	_
45-35	6594-6596	FP	_
45-36	6597-6598	,	_
45-37	6599-6602	SFG	_
45-38	6603-6604	,	_
45-39	6605-6608	MFG	_
45-40	6609-6610	,	_
45-41	6611-6614	and	_
45-42	6615-6618	IFG	_
45-43	6619-6620	)	_
45-44	6621-6623	as	_
45-45	6624-6627	the	_
45-46	6628-6643	within-subjects	_
45-47	6644-6651	factors	_
45-48	6652-6653	.	_

46-1	6654-6663	Follow-up	_
46-2	6664-6668	post	_
46-3	6669-6672	hoc	_
46-4	6673-6678	Tukey	_
46-5	6679-6682	HSD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
46-6	6683-6688	tests	_
46-7	6689-6693	were	_
46-8	6694-6703	performed	_
46-9	6704-6708	when	_
46-10	6709-6710	a	_
46-11	6711-6716	group	_
46-12	6717-6727	difference	_
46-13	6728-6731	was	_
46-14	6732-6737	found	_
46-15	6738-6739	.	_

47-1	6740-6748	Relative	_
47-2	6749-6755	volume	_
47-3	6756-6757	(	_
47-4	6758-6763	given	_
47-5	6764-6766	as	_
47-6	6767-6768	a	_
47-7	6769-6779	percentage	_
47-8	6780-6783	and	_
47-9	6784-6794	calculated	_
47-10	6795-6797	as	_
47-11	6798-6799	[	_
47-12	6800-6808	Absolute	_
47-13	6809-6819	volume/ICC	_
47-14	6820-6821	]	_
47-15	6822-6823	×	_
47-16	6824-6827	100	_
47-17	6828-6829	)	_
47-18	6830-6833	was	_
47-19	6834-6838	used	_
47-20	6839-6841	to	_
47-21	6842-6849	control	_
47-22	6850-6853	for	_
47-23	6854-6864	individual	_
47-24	6865-6869	head	_
47-25	6870-6874	size	_
47-26	6875-6877	in	_
47-27	6878-6881	the	_
47-28	6882-6897	cross-sectional	_
47-29	6898-6906	analysis	_
47-30	6907-6908	.	_

48-1	6909-6915	Groups	_
48-2	6916-6919	did	_
48-3	6920-6923	not	_
48-4	6924-6930	differ	_
48-5	6931-6944	significantly	_
48-6	6945-6947	in	_
48-7	6948-6951	ICC	_
48-8	6952-6954	at	_
48-9	6955-6959	time	_
48-10	6960-6961	1	_
48-11	6962-6963	(	_
48-12	6964-6969	F2,65	_
48-13	6970-6971	=	_
48-14	6972-6977	0.455	_
48-15	6978-6979	,	_
48-16	6980-6981	P	_
48-17	6982-6983	=	_
48-18	6984-6989	0.636	_
48-19	6990-6991	)	_
48-20	6992-6994	or	_
48-21	6995-6997	in	_
48-22	6998-7003	their	_
48-23	7004-7007	ICC	_
48-24	7008-7014	volume	_
48-25	7015-7022	changes	_
48-26	7023-7030	between	_
48-27	7031-7039	baseline	_
48-28	7040-7043	and	_
48-29	7044-7053	follow-up	_
48-30	7054-7055	(	_
48-31	7056-7057	t	_
48-32	7058-7059	=	_
48-33	7060-7065	0.489	_
48-34	7066-7067	,	_
48-35	7068-7070	df	_
48-36	7071-7072	=	_
48-37	7073-7075	67	_
48-38	7076-7077	,	_
48-39	7078-7079	P	_
48-40	7080-7081	=	_
48-41	7082-7087	0.627	_
48-42	7088-7089	)	_
48-43	7090-7091	.	_

49-1	7092-7094	Of	_
49-2	7095-7099	note	_
49-3	7100-7101	,	_
49-4	7102-7105	the	_
49-5	7106-7117	statistical	_
49-6	7118-7129	conclusions	_
49-7	7130-7138	reported	_
49-8	7139-7145	herein	_
49-9	7146-7154	remained	_
49-10	7155-7158	the	_
49-11	7159-7163	same	_
49-12	7164-7168	when	_
49-13	7169-7171	we	_
49-14	7172-7180	analyzed	_
49-15	7181-7189	absolute	_
49-16	7190-7197	volumes	_
49-17	7198-7203	using	_
49-18	7204-7207	ICC	_
49-19	7208-7210	as	_
49-20	7211-7212	a	_
49-21	7213-7222	covariate	_
49-22	7223-7224	,	_
49-23	7225-7228	and	_
49-24	7229-7233	when	_
49-25	7234-7236	we	_
49-26	7237-7245	included	_
49-27	7246-7250	only	_
49-28	7251-7256	FEAFF	_
49-29	7257-7260	who	_
49-30	7261-7265	were	_
49-31	7266-7273	bipolar	_
49-32	7274-7276	in	_
49-33	7277-7278	a	_
49-34	7279-7284	manic	_
49-35	7285-7290	phase	_
49-36	7291-7292	.	_

50-1	7293-7296	For	_
50-2	7297-7300	the	_
50-3	7301-7313	longitudinal	_
50-4	7314-7320	volume	_
50-5	7321-7331	comparison	_
50-6	7332-7333	,	_
50-7	7334-7337	the	_
50-8	7338-7348	percentage	_
50-9	7349-7351	of	_
50-10	7352-7358	volume	_
50-11	7359-7365	change	_
50-12	7366-7369	was	_
50-13	7370-7380	calculated	_
50-14	7381-7385	with	_
50-15	7386-7389	the	_
50-16	7390-7399	following	_
50-17	7400-7407	formula	_
50-18	7408-7409	:	_
50-19	7410-7413	100	_
50-20	7414-7415	×	_
50-21	7416-7417	(	_
50-22	7418-7426	Relative	_
50-23	7427-7433	Volume	_
50-24	7434-7436	at	_
50-25	7437-7443	Second	_
50-26	7444-7457	Scan–Relative	_
50-27	7458-7464	Volume	_
50-28	7465-7467	at	_
50-29	7468-7476	Baseline	_
50-30	7477-7481	Scan	_
50-31	7482-7483	)	_
50-32	7484-7485	/	_
50-33	7486-7487	(	_
50-34	7488-7496	Relative	_
50-35	7497-7503	Volume	_
50-36	7504-7506	at	_
50-37	7507-7515	Baseline	_
50-38	7516-7520	Scan	_
50-39	7521-7522	)	_
50-40	7523-7525	to	_
50-41	7526-7533	control	_
50-42	7534-7537	for	_
50-43	7538-7541	any	_
50-44	7542-7547	group	_
50-45	7548-7558	difference	_
50-46	7559-7561	in	_
50-47	7562-7569	initial	_
50-48	7570-7576	tissue	_
50-49	7577-7584	volumes	_
50-50	7585-7586	.	_

51-1	7587-7589	To	_
51-2	7590-7598	evaluate	_
51-3	7599-7604	which	_
51-4	7605-7614	subregion	_
51-5	7615-7621	showed	_
51-6	7622-7633	differences	_
51-7	7634-7641	between	_
51-8	7642-7647	times	_
51-9	7648-7649	1	_
51-10	7650-7653	and	_
51-11	7654-7655	2	_
51-12	7656-7658	in	_
51-13	7659-7662	GMV	_
51-14	7663-7668	among	_
51-15	7669-7675	groups	_
51-16	7676-7677	,	_
51-17	7678-7680	we	_
51-18	7681-7689	examined	_
51-19	7690-7693	the	_
51-20	7694-7704	percentage	_
51-21	7705-7707	of	_
51-22	7708-7719	differences	_
51-23	7720-7722	of	_
51-24	7723-7731	relative	_
51-25	7732-7739	volumes	_
51-26	7740-7743	for	_
51-27	7744-7748	each	_
51-28	7749-7758	subregion	_
51-29	7759-7764	using	_
51-30	7765-7772	one-way	_
51-31	7773-7778	ANOVA	_
51-32	7779-7783	with	_
51-33	7784-7793	follow-up	_
51-34	7794-7798	post	_
51-35	7799-7802	hoc	_
51-36	7803-7808	Tukey	_
51-37	7809-7812	HSD	_
51-38	7813-7818	tests	_
51-39	7819-7820	.	_

52-1	7821-7823	In	_
52-2	7824-7827	the	_
52-3	7828-7835	overall	_
52-4	7836-7841	group	_
52-5	7842-7852	comparison	_
52-6	7853-7862	according	_
52-7	7863-7865	to	_
52-8	7866-7876	medication	_
52-9	7877-7884	history	_
52-10	7885-7886	,	_
52-11	7887-7894	one-way	_
52-12	7895-7900	ANOVA	_
52-13	7901-7904	and	_
52-14	7905-7909	post	_
52-15	7910-7913	hoc	_
52-16	7914-7919	Tukey	_
52-17	7920-7923	HDS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
52-18	7924-7929	tests	_
52-19	7930-7934	were	_
52-20	7935-7944	performed	_
52-21	7945-7946	.	_

53-1	7947-7950	The	_
53-2	7951-7963	correlations	_
53-3	7964-7971	between	_
53-4	7972-7975	the	_
53-5	7976-7981	total	_
53-6	7982-7988	scores	_
53-7	7989-7991	of	_
53-8	7992-7996	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
53-9	7997-8000	and	_
53-10	8001-8011	medication	_
53-11	8012-8018	dosage	_
53-12	8019-8023	were	_
53-13	8024-8032	analyzed	_
53-14	8033-8035	at	_
53-15	8036-8041	times	_
53-16	8042-8043	1	_
53-17	8044-8047	and	_
53-18	8048-8049	2	_
53-19	8050-8052	to	_
53-20	8053-8061	evaluate	_
53-21	8062-8065	any	_
53-22	8066-8077	association	_
53-23	8078-8085	between	_
53-24	8086-8093	symptom	_
53-25	8094-8102	severity	_
53-26	8103-8106	and	_
53-27	8107-8118	neuroleptic	_
53-28	8119-8125	dosage	_
53-29	8126-8127	.	_

54-1	8128-8130	To	_
54-2	8131-8140	eliminate	_
54-3	8141-8144	any	_
54-4	8145-8152	outlier	_
54-5	8153-8156	and	_
54-6	8157-8160	any	_
54-7	8161-8174	non-normality	_
54-8	8175-8182	effects	_
54-9	8183-8184	,	_
54-10	8185-8187	we	_
54-11	8188-8192	used	_
54-12	8193-8201	Spearman	_
54-13	8202-8203	’	_
54-14	8204-8205	s	_
54-15	8206-8209	rho	_
54-16	8210-8213	for	_
54-17	8214-8219	these	_
54-18	8220-8228	analyses	_
54-19	8229-8230	.	_

55-1	8231-8242	Hyunh-Feldt	_
55-2	8243-8253	correction	_
55-3	8254-8257	was	_
55-4	8258-8262	used	_
55-5	8263-8267	when	_
55-6	8268-8278	sphericity	_
55-7	8279-8284	could	_
55-8	8285-8288	not	_
55-9	8289-8291	be	_
55-10	8292-8299	assumed	_
55-11	8300-8302	in	_
55-12	8303-8306	the	_
55-13	8307-8312	ANOVA	_
55-14	8313-8314	.	_

56-1	8315-8317	To	_
56-2	8318-8326	evaluate	_
56-3	8327-8330	the	_
56-4	8331-8340	magnitude	_
56-5	8341-8343	of	_
56-6	8344-8349	group	_
56-7	8350-8361	differences	_
56-8	8362-8363	,	_
56-9	8364-8369	Cohen	_
56-10	8370-8371	’	_
56-11	8372-8373	s	_
56-12	8374-8376	f2	_
56-13	8377-8379	is	_
56-14	8380-8388	provided	_
56-15	8389-8393	when	_
56-16	8394-8399	group	_
56-17	8400-8411	comparisons	_
56-18	8412-8414	by	_
56-19	8415-8420	ANOVA	_
56-20	8421-8424	did	_
56-21	8425-8428	not	_
56-22	8429-8435	attain	_
56-23	8436-8448	significance	_
56-24	8449-8450	.	_

57-1	8451-8459	Clinical	_
57-2	8460-8467	outcome	_
57-3	8468-8471	was	_
57-4	8472-8481	evaluated	_
57-5	8482-8484	as	_
57-6	8485-8488	the	_
57-7	8489-8499	percentage	_
57-8	8500-8502	of	_
57-9	8503-8509	change	_
57-10	8510-8512	in	_
57-11	8513-8519	factor	_
57-12	8520-8526	scores	_
57-13	8527-8529	in	_
57-14	8530-8534	BPRS	_
57-15	8535-8540	using	_
57-16	8541-8544	the	_
57-17	8545-8554	following	_
57-18	8555-8563	equation	_
57-19	8564-8565	:	_
57-20	8566-8569	100	_
57-21	8570-8571	×	_
57-22	8572-8573	(	_
57-23	8574-8579	Score	_
57-24	8580-8582	at	_
57-25	8583-8589	Second	_
57-26	8590-8600	Scan–Score	_
57-27	8601-8603	at	_
57-28	8604-8612	Baseline	_
57-29	8613-8617	Scan	_
57-30	8618-8619	)	_
57-31	8620-8621	/	_
57-32	8622-8623	(	_
57-33	8624-8629	Score	_
57-34	8630-8632	at	_
57-35	8633-8641	Baseline	_
57-36	8642-8646	Scan	_
57-37	8647-8648	)	_
57-38	8649-8650	.	_

58-1	8651-8653	We	_
58-2	8654-8658	also	_
58-3	8659-8663	used	_
58-4	8664-8672	Spearman	_
58-5	8673-8674	’	_
58-6	8675-8676	s	_
58-7	8677-8680	rho	_
58-8	8681-8683	to	_
58-9	8684-8691	compute	_
58-10	8692-8704	associations	_
58-11	8705-8712	between	_
58-12	8713-8716	ROI	_
58-13	8717-8723	volume	_
58-14	8724-8730	change	_
58-15	8731-8734	for	_
58-16	8735-8740	those	_
58-17	8741-8745	ROIs	_
58-18	8746-8753	showing	_
58-19	8754-8765	significant	_
58-20	8766-8772	change	_
58-21	8773-8776	and	_
58-22	8777-8780	the	_
58-23	8781-8790	following	_
58-24	8791-8800	variables	_
58-25	8801-8802	:	_
58-26	8803-8804	1	_
58-27	8805-8806	)	_
58-28	8807-8815	clinical	_
58-29	8816-8823	symptom	_
58-30	8824-8831	outcome	_
58-31	8832-8833	(	_
58-32	8834-8838	e.g.	_
58-33	8839-8840	,	_
58-34	8841-8853	longitudinal	_
58-35	8854-8861	changes	_
58-36	8862-8864	in	_
58-37	8865-8869	BPRS	_
58-38	8870-8879	subscales	_
58-39	8880-8881	,	_
58-40	8882-8892	conceptual	_
58-41	8893-8908	disorganization	_
58-42	8909-8918	component	_
58-43	8919-8920	,	_
58-44	8921-8924	and	_
58-45	8925-8930	total	_
58-46	8931-8937	scores	_
58-47	8938-8939	)	_
58-48	8940-8941	;	_
58-49	8942-8945	and	_
58-50	8946-8947	2	_
58-51	8948-8949	)	_
58-52	8950-8959	interscan	_
58-53	8960-8968	interval	_
58-54	8969-8970	.	_

